Recombinant Vaccines Market: Product Innovation and Improvement in Vaccine Manufacturing Infrastructure Expected to Impact Revenue Growth over the Forecast Period: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

  • Published: 2018-11-22
  • Report Code: REP-GB-7757

An Incisive, In-depth Analysis on the Recombinant Vaccines Market

This study offers a comprehensive, 360 degree analysis on the Recombinant Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Recombinant Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Improving Pipeline of New Pharmaceutical Products – Main Priority of Manufacturers

Various recombinant vaccines manufacturers have allotted a new capital framework to help shape their strategic priorities. Improving pipelines for new pharmaceutical products is the main priority for recombinant vaccines manufacturers and has the potential for a marked improvement in their performance. Manufacturers are investing behind their key recombinant vaccines, which is expected to drive growth the growth of the market in the coming years.

Increasing government initiatives for using recombinant vaccines in North, Europe, Latin America, and Asia pacific region is fueling the growth of the Recombinant Vaccines market. The growing demand for sustainable & optimized healthcare has increased the demand for Recombinant Vaccines. Moreover, ease of application of Recombinant Vaccines and the availability of Recombinant Vaccines through traditional supply chains are leading to increasing adoption rates of Recombinant Vaccines among distribution channel.

Lucrative Absolute Dollar Opportunities for Key Players in the Recombinant Vaccines Market

Recombinant vaccines haven’t infiltrated healthcare settings, especially in Middle East, Africa, and APEJ. Large number of patients are not aware about recombinant vaccines in not only the developing economies, but also a considerable portion of developed economies. Market players are yet to market recombinant vaccines efficiently in order to exploit their full market potential. Awareness, advertisement, and proper marketing and are expected to help grab lucrative revenue opportunities over the forecast period. Although the adoption rate of recombinant vaccines is moderate in hospital settings globally, it poses a great market potential for manufacturers.

Recombinant Vaccines to Gain Popularity over the Forecast Period

Recombinant vaccines are projected to gain popularity as they provide great benefits for the patient, reduced side effect profiles, and reduced costs associated with therapeutic intervention as the hospital expenditure is reduced using recombinant vaccines.

80% Revenue Contribution by Leading Manufacturers in the Recombinant Vaccines Market

The recombinant vaccines market is mainly dominated by global manufactures. These manufacturers of recombinant vaccines are competing based on adoption of their respective recombinant vaccines. The increasing awareness about recombinant vaccines and a growing demand for optimized & sustainable healthcare has increased the revenue opportunity for the global manufacturers. Companies like GlaxoSmithKline plc, and Merck & Co Inc, hold more than 80% revenue share in the global recombinant vaccines market. Launching novel products is one of the main focus of key market players. Also, companies operating in the recombinant vaccines market are collaborating with retailers and local distributors in order to increase the penetration of their respective recombinant vaccines.

Recombinant Vaccines Market Witnessing Considerable Growth in Asia Pacific

According to the discussions held with key opinion leaders in the recombinant vaccines market, a substantial growth has been witnessed in Asia Pacific market for recombinant vaccines market. Manufacturers in China & APEC are estimated to grow significantly in the recombinant vaccines market.

Existing Alternate Product Categories Pose Challenges to the Growth of the Recombinant Vaccines Market

Recombinant vaccines face stiff competition from parallel product categories such as live attenuated vaccines. These vaccines offer broad spectrum immunity, and also reduce the number of dosages required. Attenuated vaccines are also known to be effective in stimulating both humoral as well as cellular immune responses. However, live attenuated vaccines in recombinant form could lead to disease transmission in immune-compromised hosts, which at times deter usage.

Competitive Landscape

The company’s report titled “Recombinant Vaccines Market” provides detailed information about the growth parameters of the companies operating in the recombinant vaccines market. It includes detailed assessment of the competitive environment in the recombinant vaccines market. The market study provides comprehensive data on each stakeholder in the recombinant vaccines market, including GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG. The report provides readers with all-encompassing data on each recombinant vaccine manufacturer’s revenue shares, winning strategies, and latest information on key strategies in the recombinant vaccines market.

Definition

Subunit recombinant vaccines are derived from killed vaccines. Their synthesis is non-toxic in nature. They contain highly immunogenic microbial antigens and are made with the help of recombinant DNA technology. Worth noting that the antigen component of subunit vaccines is covalently linked to a carrier, mostly a protein.

Attenuated recombinant vaccines are designed to specifically attenuate the microbe. Advantage of this type is mutant lesion in the microbe is specific, rather than randomly placed. These vaccines can be produced rapidly to meet sudden demands. Also it is easy to track the surveillance of these vaccines to revert back to virulence.

About the Report

The study on the recombinant vaccines market was recently published by the company, which provides comprehensive information about the most important market dynamics that prove instrumental in the growth of the recombinant vaccines market during 2018-2026. Companies in the recombinant vaccines market can find the most accurate quantitative and qualitative information about the growth parameters of the other recombinant vaccine manufacturers, which can help them develop data-driven business strategies in the coming future.

Segmentation

The report on the recombinant vaccines market provides salient information on market players. The recombinant vaccines market is segmented by region, product type, application, and distribution channel, to analyze segment-wise growth of the recombinant vaccines market. Based on regions, the recombinant vaccines market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA). The recombinant vaccines market by product type is segmented intosubunit recombinant vaccines, attenuated recombinant vaccines, vector recombinant vaccines. By application, the recombinant vaccines market is segregated into human, and veterinary recombinant vaccines. By distribution channel, the recombinant vaccines market is segregated into hospitals, private clinics & dispensaries, retail pharmacies & others.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors affecting the recombinant vaccines market during the forecast period. Additionally, the report also contains valuable information that can provide recombinant vaccines manufacturers with answers to critical questions, such as

  • Which types of products account for the maximum demand for recombinant vaccines market? Why is it so?

  • Why are the sales of recombinant vaccines services and products highest in North America? What are the factors customers seek in Recombinant Vaccines?

  • Which factors are influencing the strategies of players in the recombinant vaccines market?

  • What are the current trends adopted by various companies?

  • What are the strategies being applied by the manufacturers in order to sustain themselves in the competitive market?

Research Methodology

The process of market research followed by the company commences with extensive secondary research of the recombinant vaccines market. We have obtained industry-validated, historic, and current data about the demand for recombinant vaccines across the globe. Comprehensive secondary research was followed by extensive and in-depth primary research, where detailed information about the recombinant vaccines market was obtained in terms of value (US$ Million). Based on thorough secondary and primary research of the growth parameters of the recombinant vaccines market, we have come up with the most precise forecast on how the recombinant vaccines market will grow during the forecast period.

A recent market study published by the company – “Recombinant Vaccines Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028” consists a comprehensive assessment of the most important market dynamics. On conducting a thorough research on the historic as well as current growth parameters of the Recombinant Vaccines market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the Recombinant Vaccines market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the Recombinant Vaccines market in the upcoming years. The report provides detailed information about the current and future growth prospects of the Recombinant Vaccines market in the most comprehensive way for the better understanding of readers.

Chapter 1 – Executive Summary

The report commences with the executive summary of the Recombinant Vaccines market report, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of leading segments of the Recombinant Vaccines market.

Chapter 2 – Market Introduction

Readers can find detailed taxonomy and the definition of the Recombinant Vaccines market in this chapter, which helps readers to understand the basic information about the Recombinant Vaccines market. This section also considers the factors included and excluded for the purpose of this report.

Chapter 3 – Opportunity Analysis

Readers can find various macro-economic factors associated with the growth of Recombinant Vaccines, which would help them track the market current scenario, with key inferences drawn from historical data, current trends, and future prospects. This section also consists of an opportunity analysis conducted by FMI.

Chapter 4 –Market Dynamics

This chapter highlights the key market dynamics including the drivers, restraints and trends. Both supply-side drivers and demand-side drivers are explained well in this chapter. In this chapter will readers can understand the factors which are propelling the growth of the market along with the factors which may deter the growth of the market. Also readers will understand the key trends followed by the leading manufacturer in the Recombinant Vaccines market.

Chapter 5 – Key Inclusions

This section highlights Recombinant Vaccines Prices by product type in the regions included in the report, and Pipeline Analysis

Chapter 6 – North America Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes detailed analysis of the growth of the North America Recombinant Vaccines market along with the country-wise assessment including the U.S. and Canada. Readers can also find regional trends, historical trends, and market growth based on product type, application, distribution channel and country of Recombinant Vaccines in the North American region.

Chapter 7 – Latin America Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes detailed analysis of the growth of the Latin America Recombinant Vaccines market along with the country-wise assessment including the Brazil and Mexico. Readers can also find regional trends, historical trends, and market growth based on product type, application, distribution channel and country of Recombinant Vaccines in the Latin American region.

Chapter 8 – Western Europe Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Important growth prospects of the Recombinant Vaccines market based on its product types, application, and distribution channels in several European countries, such as EU4, UK, Nordics, Benelux, Poland and Rest of Europe are included in this chapter.

Chapter 9 – Eastern Europe Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Important growth prospects of the Recombinant Vaccines market based on its product types, application, and distribution channels in several European countries, such as Russia, Poland and Rest of Europe are included in this chapter.

Chapter 10 – APEJ Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

India, China, ASEAN, Australia and New Zealand are the leading countries in the APECJ region that are the prime subject of assessment to obtain growth prospects of the APECJ Recombinant Vaccines market in this chapter. Readers can find thorough information about the growth parameters of the APECJ Recombinant Vaccines market during the period 2018-2028.

Chapter 11 – MEA Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter provides information on how the Recombinant Vaccines market will grow in the major countries in MEA region, such as GCC Countries and South Africa, during the period 2013-2026.

Chapter 12 – Japan Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find important factors that can make a huge impact on the growth of the Recombinant Vaccines market in Japan based on the market segmentation, during the forecast period. This chapter provides the overview of regulations, drivers, restraints, and trends in the Japan Recombinant Vaccines market.

Chapter 13 – Market Structure Analysis

This chapter included the market structure by tier of companies for Recombinant Vaccines Market. This chapter also included a Company share analysis for various key players in the market.

Chapter 14 – Competition Analysis and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the Recombinant Vaccines market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Market players featured in the report include GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG

Chapter 15 – Global Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Region

This chapter explains how the Recombinant Vaccines market will grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APEJ), Middle East & Africa (MEA), and Japan.

Chapter 16 – Global Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Product Type

Based on the product type, the Recombinant Vaccines market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. In this chapter, readers can find information about key trends and developments in the Recombinant Vaccines market and market attractive analysis based on the product type for each region.

Chapter 17 – Global Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Application

Based on the Application, the Recombinant Vaccines market is segmented into Human & Veterinary. In this chapter, readers can find information about key trends and developments in the Recombinant Vaccines market and market attractive analysis based on Application.

Chapter 18 – Global Recombinant Vaccines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Distribution Channel

Based on the Distribution channel, the Recombinant Vaccines market is segregated into hospitals, Private Clinics & dispensaries, retail pharmacies and others centers. In this chapter, readers can find information about key trends and developments in the Recombinant Vaccines market and market attractive analysis based on Distribution channel.

Chapter 19 – Assumptions & Acronyms Used

This chapter included various assumptions considered for the calculating the market size for Recombinant Vaccines Market

Chapter 20 – Research Methodology

This chapter helps readers to understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the Recombinant Vaccines market.

Recombinant Vaccines Market Reports - Table of Contents

Recombinant Vaccines Market Reports - List of Tables

  1. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  2. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  3. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  4. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  5. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  6. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  7. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  8. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  9. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  10. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  11. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  12. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  13. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  14. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  15. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  16. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  17. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  18. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  19. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  20. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  21. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  22. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  23. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  24. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  25. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  26. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  27. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  28. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  29. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  30. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  31. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

Recombinant Vaccines Market Reports - List of Figures

  1. North America Recombinant Vaccines Market, Snapshot

  2. North America Recombinant Vaccines Market Value Share, by Country (2017)

  3. North America Recombinant Vaccines Market Value Share, by Product Type (2017)

  4. North America Recombinant Vaccines Market Value Share, by Application Type (2017)

  5. North America Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  6. North America Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  7. North America Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  8. North America Recombinant Vaccines Market Attractiveness Analysis, By Country

  9. North America Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  10. North America Recombinant Vaccines Market Attractiveness Analysis, By Application

  11. North America Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  12. Latin America Recombinant Vaccines Market, Snapshot

  13. Latin America Recombinant Vaccines Market Value Share, by Country (2017)

  14. Latin America Recombinant Vaccines Market Value Share, by Product Type (2017)

  15. Latin America Recombinant Vaccines Market Value Share, by Application Type (2017)

  16. Latin America Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  17. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  18. Latin America Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  19. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Country

  20. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  21. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Application

  22. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  23. Western Europe Recombinant Vaccines Market, Snapshot

  24. Western Europe Recombinant Vaccines Market Value Share, by Country (2017)

  25. Western Europe Recombinant Vaccines Market Value Share, by Product Type (2017)

  26. Western Europe Recombinant Vaccines Market Value Share, by Application Type (2017)

  27. Western Europe Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  28. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  29. Western Europe Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  30. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Country

  31. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  32. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Application

  33. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  34. Eastern Europe Recombinant Vaccines Market, Snapshot

  35. Eastern Europe Recombinant Vaccines Market Value Share, by Country (2017)

  36. Eastern Europe Recombinant Vaccines Market Value Share, by Product Type (2017)

  37. Eastern Europe Recombinant Vaccines Market Value Share, by Application Type (2017)

  38. Eastern Europe Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  39. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  40. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  41. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Country

  42. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  43. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Application

  44. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  45. APEJ Recombinant Vaccines Market, Snapshot

  46. APEJ Recombinant Vaccines Market Value Share, by Country (2017)

  47. APEJ Recombinant Vaccines Market Value Share, by Product Type (2017)

  48. APEJ Recombinant Vaccines Market Value Share, by Application Type (2017)

  49. APEJ Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  50. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  51. APEJ Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  52. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Country

  53. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  54. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Application

  55. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  56. MEA Recombinant Vaccines Market, Snapshot

  57. MEA Recombinant Vaccines Market Value Share, by Country (2017)

  58. MEA Recombinant Vaccines Market Value Share, by Product Type (2017)

  59. MEA Recombinant Vaccines Market Value Share, by Application Type (2017)

  60. MEA Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  61. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  62. MEA Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  63. MEA Recombinant Vaccines Market Attractiveness Analysis, By Country

  64. MEA Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  65. MEA Recombinant Vaccines Market Attractiveness Analysis, By Application

  66. MEA Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  67. Japan Recombinant Vaccines Market, Snapshot

  68. Japan Recombinant Vaccines Market Value Share, by Product Type (2017)

  69. Japan Recombinant Vaccines Market Value Share, by Application (2017)

  70. Japan Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  71. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  72. Japan Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  73. Japan Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  74. Japan Recombinant Vaccines Market Attractiveness Analysis, By Application

  75. Japan Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  76. Global Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  77. Global Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  78. Global Recombinant Vaccines Market Attractiveness Analysis, By Region

  79. Global Recombinant Vaccines Market Value Share Analysis, By Region, 2017 & 2028

  80. Global Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  81. Global Recombinant Vaccines Market Value Share Analysis, By Product Type, 2017 & 2028

  82. Global Recombinant Vaccines Market Attractiveness Analysis, By Application Type

  83. Global Recombinant Vaccines Market Value Share Analysis, By Application Type, 2017 & 2028

  84. Global Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  85. Global Recombinant Vaccines Market Value Share Analysis, By Distribution Channel, 2017 & 2028

Get in touch

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology